MedTrace Logo

Role of CD133 & Microsatellite Status in Evaluation of Rectosigmoid Cancer Young Adults Received Neoadjuvant Treatment

NCT03002727 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-05-08

No results posted yet for this study

Summary

Microsatellite instability is more common in colorectal cancer ( CRC) young patient which is associated with good prognosis and is considered as a predictor for good response to preoperative chemoradiotherapy. Counting of ( cluster of differentiation) CD 133 +ve cells ,as a marker for enrichment with colorectal cancer stem cells ,is considered as a prognostic marker for poor survival and predictor for radio-resistance. Correlation between microsatellite status ( MS) and CD133 count has not yet studied especially in young patients with rectosigmoid cancer. So the investigators hypothesize that there is correlation between microsatellite status, CD133+ve cells count , occurrence of CRC in young patients and resistance to standard treatment regimen. Improvement of response to treatment and choice of the best regime to avoid non beneficial treatment modality are the goal of this study.

Conditions

  • Colorectal Cancer Genetics
  • Young Adult

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ola N Abdl fattah, Ass.Prof · Assiut University

  • Dalia A El sers, Ass.prof · Assiut University

  • Mahmoud R Shehata, Lecturer · Assiut University

  • Samia A Ali, Prof · Assiut University

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-12-31
Completion
2019-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03002727 on ClinicalTrials.gov